TN8 Stock Overview
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Thermo Fisher Scientific Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$557.30 |
| 52 Week High | US$557.30 |
| 52 Week Low | US$398.00 |
| Beta | 0.80 |
| 1 Month Change | 5.83% |
| 3 Month Change | 11.89% |
| 1 Year Change | 14.01% |
| 3 Year Change | 43.93% |
| 5 Year Change | 127.24% |
| Change since IPO | 2,912.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| TN8 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 10.4% | -5.1% | 1.7% |
| 1Y | 14.0% | -9.0% | 2.3% |
Return vs Industry: TN8 exceeded the German Life Sciences industry which returned -9% over the past year.
Return vs Market: TN8 exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| TN8 volatility | |
|---|---|
| TN8 Average Weekly Movement | 3.1% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TN8 has not had significant price volatility in the past 3 months.
Volatility Over Time: TN8's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 122,000 | Marc Casper | www.thermofisher.com |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
Thermo Fisher Scientific Inc. Fundamentals Summary
| TN8 fundamental statistics | |
|---|---|
| Market cap | €205.52b |
| Earnings (TTM) | €5.63b |
| Revenue (TTM) | €39.62b |
36.5x
P/E Ratio5.2x
P/S RatioIs TN8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TN8 income statement (TTM) | |
|---|---|
| Revenue | US$42.49b |
| Cost of Revenue | US$25.37b |
| Gross Profit | US$17.12b |
| Other Expenses | US$11.09b |
| Earnings | US$6.03b |
Last Reported Earnings
Mar 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.81 |
| Gross Margin | 40.29% |
| Net Profit Margin | 14.20% |
| Debt/Equity Ratio | 78.0% |
How did TN8 perform over the long term?
See historical performance and comparison